Patents Assigned to Pathologica, LLC
  • Controlled release oral pharmaceutical dosage forms comprising MGBG
    Patent number: 10881626
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: January 5, 2021
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Methods and compositions for treatment of demyelinating diseases
    Patent number: 10350178
    Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
    Patent number: 10292950
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 21, 2019
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Methods and compositions for treatment of demyelinating diseases
    Patent number: 10085955
    Abstract: Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 2, 2018
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • Regulation of osteopontin
    Patent number: 9867794
    Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 16, 2018
    Assignee: Pathologica LLC
    Inventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do
  • Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
    Patent number: 9675566
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 13, 2017
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Controlled release oral pharmaceutical dosage forms comprising MGBG
    Patent number: 9668988
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 6, 2017
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
    Patent number: 9616035
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: April 11, 2017
    Assignee: PATHOLOGICA, LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Delayed release oral pharmaceutical dosage forms comprising MGBG
    Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Method of Treatment with Anti-Inflammatory and Analgesic Compounds Which are GI-, Renal-, and Platelet-Sparing
    Publication number: 20140187643
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.
    Type: Application
    Filed: September 23, 2013
    Publication date: July 3, 2014
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
    Publication number: 20140051765
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • REGULATION OF OSTEOPONTIN
    Publication number: 20130317113
    Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.
    Type: Application
    Filed: April 18, 2013
    Publication date: November 28, 2013
    Applicant: Pathologica LLC
    Inventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do
  • Regulation of osteopontin
    Patent number: 8445540
    Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: May 21, 2013
    Assignee: Pathologica LLC
    Inventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do
  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
    Publication number: 20120289604
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
    Publication number: 20120269891
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Application
    Filed: January 19, 2012
    Publication date: October 25, 2012
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Pharmaceutical for oral delivery comprising MGBG
    Patent number: 8258186
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: September 4, 2012
    Assignee: Pathologica, LLC
    Inventors: John McKearn, Jeremy Blitzer
  • METHODS FOR MODULATING MACROPHAGE PROLIFERATION IN OCULAR DISEASE USING POLYAMINE ANALOGS
    Publication number: 20120219970
    Abstract: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also provides methods for aiding diagnosis and monitoring therapy of an ocular disease such as ARMD.
    Type: Application
    Filed: May 11, 2012
    Publication date: August 30, 2012
    Applicant: PATHOLOGICA LLC
    Inventor: Michael McGrath
  • Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
    Patent number: 8198334
    Abstract: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also provides methods for aiding diagnosis and monitoring therapy of an ocular disease such as ARMD.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: June 12, 2012
    Assignee: Pathologica LLC
    Inventor: Michael McGrath
  • PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
    Publication number: 20110112199
    Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
    Type: Application
    Filed: July 16, 2010
    Publication date: May 12, 2011
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • REGULATION OF OSTEOPONTIN
    Publication number: 20080262092
    Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.
    Type: Application
    Filed: March 10, 2008
    Publication date: October 23, 2008
    Applicant: PATHOLOGICA LLC.
    Inventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do